A fast-improving pipeline of drugs is attracting pharma dealmakers, putting pressure on U.S. biotechs and the VC firms that back them. Learn more in
this Trendline.
The arrival of vaccine skeptic Robert F. Kennedy Jr. as U.S. health secretary threatens to upend vaccination policy in the country, just as a measles outbreak takes root. Explore what the future holds for the market in this Trendline.
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal Biotech that is off to a strong sales start.
Amidst an industry-wide shift to digital solutions, GenAI is helping biopharma leaders create a frictionless contact center and deliver personalized experiences. Learn more in this playbook.
